Market Newsdesk

Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) —


Daxor Corporation


(Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management.

“Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda’s proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility,” said Michael Feldschuh, CEO and President of Daxor Corporation.

Before joining Daxor, Linda has held several senior leadership roles with major medical device companies including OsteoCentric Technologies and Integra LifeSciences where she oversaw multiple product launches through the entire product development process including software and hardware design, testing, regulatory clearance, initial build and launch. She earned her Bachelor of Science degree in biomedical engineering from the University of Iowa and is an inventor on a U.S. patent for a bone plate system for repair of proximal humeral fracture.

“It is an exciting time to be joining Daxor as we prepare to submit our next generation systems in preparation for the most important technology launch for the company in twenty years. I look forward to working with the entire Oak Ridge team, utilizing their expertise to streamline procedures, eliminate redundancies, plan for future growth, and build upon the existing energized environment,” said Linda Cooper.

About Daxor Corporation

Daxor Corporation
(Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
[email protected]

PHOENIX, Feb. 17, 2023 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC) today announced that Nick Girardi, Senior Director of Treasury & Investor Relations, will participate in private investor meetings at the J.P. Morgan Global High Yield and Leveraged Finance Conference in Miami, FL on March 7, 2023.

About WillScot Mobile Mini

WillScot Mobile Mini trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 240 branch locations and additional drop lots throughout the United States, Canada, and Mexico.

Additional Information and Where to Find It

Additional information can be found on the company’s website at www.willscotmobilemini.com 

Media Contact Information

Jake Saylor

[email protected]

Investor Contact Information

Nick Girardi

[email protected]

LOS ANGELES, Feb. 17, 2023 (GLOBE NEWSWIRE) — FAT
(Fresh. Authentic. Tasty.) Brands Inc. (NASDAQ: FAT) (“FAT Brands” or the “Company”), a leading global franchising company and parent company of iconic brands including Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, Fazoli’s and 12 other restaurant concepts today announced that the Company will host a conference call to review its fourth quarter and fiscal year 2022 financial results on Wednesday, February 22, 2023 at 5:00 PM ET. A press release with fourth quarter and fiscal year 2022 financial results will be issued prior to the conference call that day.

The conference call can be accessed live over the phone by dialing 1-877-704-4453 from the U.S. or 1-201-389-0920 internationally. A replay will be available after the call until Wednesday, March 1, 2023 and can be accessed by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 internationally. The passcode is 13735781. Hosting the call will be Andy Wiederhorn, President and Chief Executive Officer, and Ken Kuick, Chief Financial Officer.

The conference call will also be webcast live from the corporate website at www.fatbrands.com, under the “Investors” section. A replay of the webcast will be available through the corporate website shortly after the call has concluded.

About FAT (Fresh. Authentic. Tasty.) Brands

FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets and develops fast casual, casual and polished casual dining restaurant concepts around the world. The Company currently owns 17 restaurant brands: Round Table Pizza^®, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Native Grill & Wings, Pretzelmaker, Elevation Burger, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises and owns over 2,300 units worldwide. For more information on FAT Brands, please visit http://www.fatbrands.com.

Investor Relations:

ICR
Michelle Michalski
[email protected]
646-277-1224

Media Relations:

Erin Mandzik
[email protected]
860-212-6509

###

MitoCareX established its initial cloud-based computing infrastructure

TEL AVIV, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that its MitoCareX Bio Ltd. (“MitoCareX Bio”) joint venture , which focuses on the discovery and development of potential drugs for cancer, rare diseases and other life-threatening conditions, has achieved its first milestone pursuant to the March 10, 2022 Founders and Investment Agreement with respect to MitoCare X Bio (the “MitoCareX Bio Agreement”). 

The first milestone refers to the establishment of MitoCareX Bio’s cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system. The system is harnessed to investigating mitochondrial carriers that are crucial for cell viability.

As a result of MitoCareX Bio meeting this milestone, SciSparc will invest an additional $400,000 in MitoCareX Bio and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.

As mitochondrial carriers hold a significant role in transporting necessary metabolites for cell functioning and survival across the inner mitochondrial membranes, the Company believes that various life-threatening conditions, such as cancer and rare diseases, might be treated by regulating the function of mitochondrial carriers. In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter family.

MitoCareX Bio is currently performing virtual screening activities as well as further developing its computationally based drug discovery platform to enable its planned machine learning capabilities. MitoCareX Bio’s innovative research is partly based upon successful proof-of-concept experiments previously performed in the United Kingdom.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company also has a wholly-owned subsidiary whose business focusses on the sale of hemp-based products on the Amazon.com marketplace.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses advantages and benefits of MitoCareX Bio’s cloud computing and that it is expected to allow future expansion into machine learning system,that SciSparc willinvest an additional $400,000 and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%, and the Company’s belief that various life-threatening conditions, such as cancer and rare diseases, might be treated by regulating the function of mitochondrial carriers. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward- looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2022, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:




[email protected]


Tel: +972-3-6167055

LONDON, Feb. 17, 2023 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (“Arqit”), a global leader in quantum encryption technology, today announced that it has entered into a definitive securities purchase agreement with several institutional investors (the “Securities Purchase Agreement”) for the sale and purchase of 10 million shares of the Company’s ordinary shares, $0.0001 par value each (the “Ordinary Shares”), together with warrants (the “Warrants) to purchase up to 7.5 million Ordinary Shares at a combined offering price of $2.00 per Ordinary Share and accompanying warrant, in a registered direct offering (the “Offering”). The Warrants will have an exercise price of $2.00 per Ordinary Share, will become exercisable commencing the date of issuance and will expire five years from the initial exercise date. The Company expects the Offering to close on or about 22 February 2023, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the sole placement agent for the offering.

The gross proceeds of the Offering are expected to be approximately $20 million, before deducting the placement agent’s fees and other offering expenses. Arqit intends to use the net proceeds from this offering to enhance international customer service capabilities in support of the growth of its recently announced channel partnerships and for general corporate purposes.

A “shelf” registration statement on Form F-3, as amended (File Number 333-268786), relating to the offered securities was initially filed with the Securities and Exchange Commission (“SEC”) on 14 December 2022 and was declared effective on 30 December 2022. The Offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement. A prospectus supplement and accompanying prospectus relating to the Offering will be filed with the SEC. Electronic copies of the prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these Company securities, nor shall there be any sale of these Company securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Arqit

Arqit supplies a unique quantum safe encryption Platform-as-a-Service which makes the communications links or data at rest of any networked device or cloud machine secure against current and future forms of attack – even from a quantum computer. Arqit’s product, QuantumCloud™, enables any device to download a lightweight software agent, which can create encryption keys in partnership with any number of other devices. The keys are computationally secure, optionally one-time use and zero trust.  QuantumCloud™ can create limitless volumes of keys in limitless group sizes and can regulate the secure entrance and exit of a device in a group. Arqit believes it is the only company in the market to have achieved Independent Assurance Review of its Security Proof demonstrating that the software can produce encryption keys which are zero trust and provably secure, i.e. permanently safe against attack from even a full scale quantum computer. This review was conducted by the GCHQ Accredited Centre of Excellence in Cyber Security at the University of Surrey. The addressable market for QuantumCloud™ is every connected device.  Arqit was recently awarded the Innovation in Cyber award at the National Cyber Awards.

Media relations enquiries:

Arqit: [email protected]
FTI Consulting: [email protected]

Investor relations enquiries:

Arqit:

[email protected]


Gateway:

[email protected]

Caution About Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements are based on Arqit’s expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Arqit’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Arqit to predict these events or how they may affect it. Except as required by law, Arqit does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date this communication is issued. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur. Uncertainties and risk factors that could affect Arqit’s future performance and cause results to differ from the forward-looking statements in this release include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against the Arqit related to the business combination, (ii) the ability to maintain the listing of Arqit’s securities on a national securities exchange, (iii) changes in the competitive and regulated industries in which Arqit operates, variations in operating performance across competitors and changes in laws and regulations affecting Arqit’s business, (iv) the ability to implement business plans, forecasts, and other expectations, and identify and realise additional opportunities, (v) the potential inability of Arqit to convert its pipeline into contracts or orders in backlog into revenue, (vi) the potential inability of Arqit to successfully deliver its operational technology, (vii) the risk of interruption or failure of Arqit’s information technology and communications system, (viii) the enforceability of Arqit’s intellectual property, and (ix) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Arqit’s annual report on Form 20-F (the “Form 20-F”), filed with the U.S. Securities and Exchange Commission (the “SEC”) on 14 December 2022 and in subsequent filings with the SEC. While the list of factors discussed above and in the Form 20-F and other SEC filings are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realisation of forward-looking statements. 

CASTLE ROCK, Colo., Feb. 17, 2023 (GLOBE NEWSWIRE) — Where Food Comes From, Inc. (WFCF) (Nasdaq: WFCF), the most trusted resource for independent, third-party verification of food production practices in North America, today announced it will release its 2022 fourth quarter and full-year financial results before the market opens on Thursday, February 23, 2023, and conduct a conference call the same day at 10:00 a.m. Mountain Time (12:00 p.m. Eastern).

Dial-in numbers for the conference call:

Domestic Toll Free: 1-877-407-8289
International: 1-201-689-8341
Conference Code: 13736422

Phone replay:

A telephone replay of the conference call will be available through March 23, 2023, as follows:
Domestic Toll Free: 1-877-660-6853
International: 1-201-612-7415
Conference Code: 13736422

About Where Food Comes From, Inc.

Where Food Comes From, Inc. is America’s trusted resource for third party verification of food production practices.  Through proprietary technology and patented business processes, the Company supports approximately 17,500 farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, consumer brands and restaurants with a wide variety of value-added services. Through its IMI Global, Validus Verification Services, SureHarvest, WFCF Organic (previously known as International Certification Services and A Bee Organic), Postelsia and Sterling Solutions units, Where Food Comes From solutions are used to verify food claims, optimize production practices and enable food supply chains with analytics and data driven insights. In addition, the Company’s Where Food Comes From® retail and restaurant labeling program uses web-based customer education tools to connect consumers to the sources of the food they purchase, increasing meaningful consumer engagement for our clients. 

Contact:

Jay Pfeiffer
Investor Relations
303-880-9000
[email protected]

SAN JOSE, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced that the company is scheduled to present at upcoming investor conferences. Details for each event are as follows:

Morgan Stanley TMT Conference in San Francisco

Monday, March 6, 2023
8:00 a.m. PST (11:00 a.m. EST)

JMP Technology Conference in San Francisco

Tuesday, March 7, 2023
1×1 Investor Meetings

Sessions which offer a webcast will be available on the “Events & Presentations” section of the Zscaler Investor Relations website at https://ir.zscaler.com.

About Zscaler

Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust Exchange protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across more than 150 data centers globally, the SSE-based Zero Trust Exchange is the world’s largest in-line cloud security platform.

Zscaler™ and the other trademarks listed at


https://www.zscaler.com/legal/trademarks


are either (i) registered trademarks or service marks or (ii) trademarks or service marks of Zscaler, Inc. in the United States and/or other countries. Any other trademarks are the properties of their respective owners.

Media Relations Contact:

Natalia Wodecki
[email protected]

Investor Relations Contact:

Bill Choi, CFA
[email protected]

MALVERN, Pa., Feb. 17, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the Retinal Vascular Disease Drug Development Summit at the Hilton Boston Logan Airport in Boston, Mass. from February 21-23, 2023.

“I am very pleased that Dr. Upadhyay will share his expertise in this specific area of retinal disease research at the Retinal Vascular Disease Drug Development Summit,” said Dr. Shankar Musunuri, Chairman, CEO & Co-Founder of Ocugen. “Through the work Dr. Upadhyay and his team are doing, Ocugen could potentially provide a viable therapeutic option to the significant percentage of people living with diabetic macular edema (DME) that are non-responders to the current standard of care.”

Presentation: Developing a Novel Therapeutic to Potentially Treat DME Patients that are Non-Responsive to Anti-VEGF Therapy
Date: Thursday, February 23, 2023
Time: 1:30 p.m. ET

Ocugen is developing OCU200—a novel fusion protein consisting of two human proteins, tumstatin and transferrin—for treating severely sight-threatening diseases like DME, diabetic retinopathy, and wet age-related macular degeneration. Patients affected by these diseases share common symptoms, such as blurriness in vision and progressive vision loss as the disease progresses. The formation of fragile and leaky new blood vessels leads to fluid accumulation in and around the retina, causing damage to vision.

The Company is currently executing IND-enabling studies for OCU200 and plans to submit an IND application in the first quarter of 2023.

About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:

Tiffany Hamilton
Head of Communications
[email protected]

NEW ALBANY, Ohio, Feb. 17, 2023 (GLOBE NEWSWIRE) — Abercrombie & Fitch Co. (NYSE: ANF), a leading, global omni-channel specialty retailer of apparel and accessories, today announced the election of Helen Vaid as an independent director, effective February 16, 2023.

Ms. Vaid, 51, was most recently the Chief Executive Officer of Foundry Brands, a digitally native brand platform. In that role, which she held until February 2023, she was responsible for accelerating the omni-channel growth of Foundry’s suite of consumer brands across a range of product categories.

Prior to joining Foundry Brands, Ms. Vaid held a number of customer-centric leadership roles, responsible for growing businesses in both the digital and physical spaces, including Global Chief Customer Officer of Pizza Hut, a subsidiary of Yum! Brands, Inc. and Vice President of Digital Store Operations and Experience at Walmart.com, a division of Walmart Inc. She also held several technology-focused roles at Hewlett Packard Enterprise. Ms. Vaid also currently serves on the board of directors for Groupon, Inc.  

“We are pleased to welcome Helen to Abercrombie & Fitch Co. She brings more than 20 years of extremely relevant experience leading customer engagement and growth strategies for a number of consumer products and platforms,” said Nigel Travis, Chairperson of the Board. “She is an industry veteran with digital expertise, who has continually been able to stay at the forefront of an ever-evolving retail landscape, while delivering value to both customers and brands.” With Ms. Vaid’s election, the company’s board of directors expands to eleven, six of whom are female.

“I am thrilled to join Abercrombie & Fitch Co.’s Board of Directors,” said Vaid. “I have been following the transformation of the company closely over the last several years and I’m honored to be a part of the next chapter,” she added. “I look forward to working with CEO Fran Horowitz, Nigel, and the rest of the board and management team to support the company, its associates and its iconic global brands as we work to deliver on A&F Co.’s strategic priorities.”

About Abercrombie & Fitch Co.:  

Abercrombie & Fitch Co. (NYSE: ANF) is a leading, global, omnichannel specialty retailer of apparel and accessories for men, women and kids through five renowned brands. The iconic Abercrombie & Fitch brand was born in 1892 and aims to make every day feel as exceptional as the start of a long weekend. abercrombie kids sees the world through kids’ eyes, where play is life and every day is an opportunity to be anything and better anything. The Hollister brand believes in liberating the spirit of an endless summer inside everyone and making teens feel celebrated and comfortable in their own skin. Gilly Hicks, offering active lifestyle products, is designed to create happiness through movement. Social Tourist, the creative vision of Hollister and social media personalities, Dixie and Charli D’Amelio, offers trend forward apparel that allows teens to experiment with their style, while exploring the duality of who they are both on social media and in real life. 

The brands share a commitment to offering products of enduring quality and exceptional comfort that allow consumers around the world to express their own individuality and style. Abercrombie & Fitch Co. operates approximately 770 stores under these brands across North America, Europe, Asia and the Middle East, as well as the e-commerce sites www.abercrombie.com, www.abercrombiekids.com, www.hollisterco.com, www.gillyhicks.com and www.socialtourist.com.

Investor Contact:  Mohit Gupta (614) 283-6751 [email protected]

Media Contact:  Kate Wagner  (614) 283-6192 [email protected]

WOODCLIFF LAKE, N.J., Feb. 17, 2023 (GLOBE NEWSWIRE) — Powerfleet, Inc. (Nasdaq: PWFL) will hold a conference call on Thursday, March 9, 2023 at 8:30 a.m. Eastern time (5:30 a.m. Pacific time) to discuss results for the fourth quarter and full year ended December 31, 2022. Financial results will be issued in a press release prior to the call.

Powerfleet management will host the presentation, followed by a question-and-answer session.

Date: Thursday, March 9, 2023
Time: 8:30 a.m. Eastern time (5:30 a.m. Pacific time)
Toll Free: 877-524-8416
International: +1-412-902-1028

The conference call will be broadcast simultaneously and available for replay here and via the investor section of the company’s website at ir.powerfleet.com.

About Powerfleet

Powerfleet (Nasdaq: PWFL; TASE: PWFL) is a global leader of internet of things (IoT) software-as-a-service (SaaS) solutions that optimize the performance of mobile assets and resources to unify business operations. Our data science insights and advanced modular software solutions help drive digital transformation through our customers’ and partners’ ecosystems to help save lives, time, and money. We help connect companies, enabling customers and their customers to realize more effective strategies and results. Powerfleet’s tenured and talented team is at the heart of our approach to partnership and tangible success. The company is headquartered in Woodcliff Lake, New Jersey, with our Pointer Innovation Center (PIC) in Israel and field offices around the globe. For more information, please visit www.Powerfleet.com.

Powerfleet Investor Contact 
Matt Glover
Gateway Group, Inc.
[email protected]
(949) 574-3860

Powerfleet Media Contact

Heather K. Smith
[email protected]
(605)203-0605